Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Effect of concomitant medication (ketoconazole, mefloquine, quinine or lopinavir/ritonavir) on exposure to artemether, dihydroartemisinin (DHA) and lumefantrine in studies undertaken in healthy volunteers

From: Understanding the pharmacokinetics of Coartem®

Concomitant medication N Change in exposure to artemether (AUC) Change in exposure to DHA (AUC) Change in exposure to lumefantrine (AUC) Change in exposure to concomitant medication (AUC)a
Ketoconazole [8] 16 ↑ 2.4-fold ↑ 1.7-fold ↑ 1.7-fold Not measured
Mefloquine [21] 42 Unchanged Unchanged ↓ 32% Unchanged
Quinine [22] 42 ↓ 46% ↓ 37% Unchanged Unchanged
Lopinavir/ritonavir [24] 13 ↓ 35% ↓ 45% ↑ 2.4-fold Unchanged
  1. a Ketoconazole, mefloquine, quinine or lopinavir/ritonavir, respectively